Trials / Conditions / Opioid-Related Disorders

Opioid-Related Disorders

297 registered clinical trials studyying Opioid-Related Disorders — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary NCT06810076	University of Pittsburgh	N/A
Recruiting	Developing a Smartphone Application to Support Veteran Opioid Use Disorder Treatment NCT06454903	VA Office of Research and Development	N/A
Completed	Erector Spinae Plane Block Versus Serratus Anterior Plane Block NCT06862752	Sisli Hamidiye Etfal Training and Research Hospital	N/A
Recruiting	Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits NCT06387290	University of Utah	Phase 3
Completed	The Acupuncture for Pain, Opioid Use Disorder and Mood NCT06543355	Albert Einstein College of Medicine	N/A
Recruiting	fMRI and Opioid Abstinence NCT06651333	Yale University	—
Active Not Recruiting	Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR) NCT06023459	Yih-Ing Hser	Phase 3
Recruiting	Psilocybin in Cancer Pain Study NCT06001749	Yvan Beaussant, MD, MSci	Phase 2
Completed	Assessing the Efficacy of Self-Driven Repetitive Artmaking Practice NCT06554431	Montefiore Medical Center	N/A
Recruiting	Clinical Trial on Deprescribing Associated With a Psychoeducational Program Using Virtual Reality for Patients NCT06964360	Badalona Serveis Assistencials	N/A
Active Not Recruiting	OUD Smartphone Services NCT06134882	Western Michigan University	N/A
Unknown	A4i-O: A Platform for Complex Behavioral Health to Address OUD NCT06215963	Centre for Addiction and Mental Health	N/A
Withdrawn	Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder NCT03804619	Stanford University	N/A
Active Not Recruiting	Tau PET Imaging in Opioid Use Disorder NCT05651516	University of Pennsylvania	EARLY_Phase 1
Enrolling By Invitation	Fatal Overdose Review Teams - Research to Enhance Surveillance Systems NCT06084221	Indiana University	N/A
Active Not Recruiting	Cryoneurolysis Prior to Total Knee Arthroplasty NCT05840276	Esbjerg Hospital - University Hospital of Southern Denmark	N/A
Completed	Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder NCT05903495	West Virginia University	N/A
Unknown	Informational App Development for mHealth for Patient Self-Management of Opioid Use Disorder NCT05859035	Biomedical Development Corporation	N/A
Recruiting	Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder NCT05336188	University of Arkansas	Phase 2
Recruiting	STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancrea NCT05603702	Indiana University	Phase 1
Active Not Recruiting	Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk NCT05657106	April M Young	N/A
Active Not Recruiting	Safe Prescription of Opioids in Primary Care NCT05577026	Region Stockholm	N/A
Completed	Social Work Assistance and Stipends for Housing (SASH) NCT05803603	University of Maryland, Baltimore	N/A
Completed	SIRI Checklist: An Integrated Hospital Model to Optimize HIV Prevention in Persons Who Inject Drugs NCT05480956	University of Alabama at Birmingham	N/A
Active Not Recruiting	Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing NCT05505227	Ohio University	N/A
Completed	Improving Health and Employment Outcomes Through Workplace Opioid Policies NCT05387408	Washington University School of Medicine	N/A
Withdrawn	Surviving Opioid Overdose With Naloxone Education and Resuscitation Trial (SOONER) NCT04740099	Unity Health Toronto	N/A
Suspended	Patients' Attitudes Toward and Experiences With Buprenorphine Treatment NCT05121428	Cambridge Health Alliance	—
Completed	Substance Use Treatment and Recovery Team NCT05086796	Cedars-Sinai Medical Center	N/A
Completed	More Individualized Care: Assessment and Recovery Through Engagement NCT05122676	Kaiser Permanente	N/A
Active Not Recruiting	Healthy Opioid Prescription Engagement NCT05141266	Jerry Cochran	N/A
Completed	Use of a GLP-1R Agonist to Treat Opioid Use Disorder NCT04199728	Milton S. Hershey Medical Center	Phase 1 / Phase 2
Unknown	Pre-operative Education Modalities to Decrease Opioid Use NCT04933084	Benaroya Research Institute	N/A
Terminated	Neurofeedback in Individuals With Substance Use Disorders NCT04188288	Yale University	N/A
Unknown	EA for Protracted Withdrawal of OUD NCT04961294	Chengdu University of Traditional Chinese Medicine	N/A
Completed	Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-stud NCT03911739	T. John Winhusen, PhD	—
Completed	Preventing Parental Opioid and/or Methamphetamine Addiction Within DHS-Involved Families: PRE-FAIR NCT05380440	Chestnut Health Systems	N/A
Terminated	Combining Neuro-Imaging and Non-Invasive Brain Stimulation for Clinical Intervention in Opioid Use Disorder NCT04495673	University of Minnesota	N/A
Unknown	Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction NCT03394911	Bubba Nicholson	Phase 3
Completed	Substance Use Treatment and Recovery Team (START) NCT04314648	RAND	N/A
Completed	An Innovative Intervention for OUD Treatment NCT04325659	Johns Hopkins University	Phase 2 / Phase 3
Completed	Neuroimaging and CBD for Opioid Use Disorder NCT04567784	Yasmin Hurd	Phase 2
Completed	Intrathecal Morphine for Robotic-assisted Laparoscopic Hysterectomy. NCT04675840	Karlstad Central Hospital	N/A
Unknown	Does ESP Block Reduce Pain and Opiates Consumption After Surgery NCT05512897	Michael Dubilet MD	N/A
Completed	Incentives to Decrease Opioid Use - Pilot NCT04235582	Wake Forest University Health Sciences	N/A
Completed	Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study NCT03911466	T. John Winhusen, PhD	—
Completed	Medication Treatment for Opioid Use Disorder in Expectant Mothers NCT03918850	T. John Winhusen, PhD	Phase 3
Enrolling By Invitation	Alliances to Disseminate Addiction Prevention and Treatment (ADAPT) NCT04499079	Indiana University	N/A
Completed	Evaluation of a Medication Disposal Program in Primary Care NCT04320004	Geisinger Clinic	N/A
Completed	De-prescribing Program to Evaluate Falls in Older Adults NCT04272671	University of North Carolina, Chapel Hill	N/A
Terminated	Slow-Release Oral Morphine for the Treatment of Opioid Use Disorder NCT03948464	M. Eugenia Socias	Phase 3
Completed	Prevalence of Chronic Pain and Its Risk Factors After a Surgical Intensive Care Unit Stay. Prospective Observa NCT04164342	University Hospital, Angers	N/A
Withdrawn	Comparison of Three Opioid Detoxification Treatment Regimens NCT03678792	University of Alabama at Birmingham	Phase 3
Active Not Recruiting	Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder NCT03950492	West Virginia University	N/A
Completed	The Kentucky Viral Hepatitis Treatment Study NCT03949764	Jennifer Havens	Phase 4
Completed	Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings NCT03698669	Boston University	N/A
Completed	Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing NCT03932799	University of Washington	—
Completed	MOms in REcovery (MORE) Study: Defining Optimal Care NCT04251208	Trustees of Dartmouth College	—
Completed	Youth Opioid Recovery Support: Improving Care Systems NCT04015115	University of Maryland, Baltimore	N/A
Terminated	Imaging Biomarker for Addiction Treatment Outcome NCT03427424	National Institute on Drug Abuse (NIDA)	—
Recruiting	Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder NCT03745339	National Institute on Drug Abuse (NIDA)	—
Unknown	Development of an Algorithm That Predicts Hypoventilation Due to an Opioid Overdose NCT03845699	RTM Vital Signs, LLC	—
Completed	Treatment of Opioid Use: Medication Adherence Therapy NCT03567356	Potomac Health Foundations	N/A
Completed	Repeated-dose Behavioral Intervention to Reduce Opioid Overdose NCT03838510	San Francisco Department of Public Health	N/A
Terminated	Recovery of Ventilation After General Anesthesia in Morbidly Obese Patients NCT03925610	Stanford University	—
Completed	Optimizing Pregnancy and Treatment Interventions for Moms 2.0 NCT03833245	University of Utah	N/A
Completed	Trial of Adherence App for Buprenorphine Treatment (TAAB) Study NCT03779997	University of Washington	N/A
Completed	Evaluation of Pharmacy Students' Perception of Opioid / Opiate Dependence NCT03859778	University Hospital, Clermont-Ferrand	—
Withdrawn	Adolescent Community Reinforcement Approach in Combination With Buprenorphine/Naloxone for Severe Opioid Use NCT03287180	Emory University	N/A
Completed	The Navigator Trial NCT03684681	Rhode Island Hospital	N/A
Completed	The OPT-IN Project NCT03526380	University of Michigan	N/A
Completed	Modified ABC: A Home-based Parenting Program for Opioid-dependent Mothers and Their Infants NCT03891628	University of Delaware	N/A
Completed	Buspirone for Opioid Tapering NCT03521960	Johns Hopkins University	Phase 1
Completed	Youth Opioid Recovery Support: A Developmentally-specific Intervention for Home Delivery of Extended Release N NCT03306368	Potomac Health Foundations	N/A
Completed	Addressing Origins of the Opioid Epidemic by Improving Prescribing for Opioid-Naive Patients NCT03377855	Weill Medical College of Cornell University	N/A
Completed	Assessment of the Satisfaction of Patient Undergoing Opioid Replacement Therapy Toward Their Management in Com NCT03961789	University Hospital, Clermont-Ferrand	—
Completed	Harnessing Placebo Effects in Methadone Treatment NCT02941809	University of Maryland, Baltimore	N/A
Terminated	Postoperative and Opioid Free Anesthesia NCT03316339	Rennes University Hospital	Phase 3
Completed	RETAIN: Retaining Opioid Users Entering Medication Assisted Treatment and Encouraging HCV/HIV Testing NCT03411265	University of Cincinnati	N/A
Completed	A Prospective Investigation of the Risks of Opioid Misuse, Abuse, and Addiction Among Patients Treated With Op NCT02751762	Member Companies of the Opioid PMR Consortium	—
Completed	Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings NCT02978417	Duke University	Phase 4
Unknown	Mobile Intervention for Young Opioid Users NCT03610672	National Development and Research Institutes, Inc.	N/A
Withdrawn	A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amoun NCT03137030	Grünenthal GmbH	Phase 1
Withdrawn	A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Mar NCT03137017	Grünenthal GmbH	Phase 1
Completed	Prescribe to Save Lives NCT03175640	Baystate Medical Center	N/A
Completed	Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers NCT03129347	National Institute on Drug Abuse (NIDA)	Phase 1
Completed	Computer-based Prescription Opioid Abuse Prevention for Adolescents NCT02737696	Dartmouth-Hitchcock Medical Center	N/A
Completed	Addressing the Risks of Long-Term Opioid Therapy in Chronic Noncancer Pain NCT03161795	Seoul National University	—
Completed	Opioid Dependence Treatment Therapies in Pregnancy NCT03098407	University of Pittsburgh	N/A
Completed	Study of Yoga vs. Health Education for Chronic Pain in Persons Receiving Opioid Agonist Therapy NCT03022890	Butler Hospital	N/A
Completed	A Tailored, Peer-delivered Intervention to Reduce Recurring Opioid Overdoses NCT02922959	University of Cincinnati	N/A
Completed	Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder NCT03143855	Virginia Commonwealth University	Phase 1
Completed	Buprenorphine Group Medical Visits in Primary Care NCT02526212	Montefiore Medical Center	Phase 3
Completed	Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia NCT02992938	University of Chile	Phase 4
Terminated	Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic NCT02741076	Member Companies of the Opioid PMR Consortium	Phase 4
Terminated	BUPrenorphine Facilitated Access and Supportive Treatment --AIM 3 NCT02902835	Montefiore Medical Center	N/A
Completed	Open-Label Treatment Extension Study NCT02896296	Indivior Inc.	Phase 3
Completed	Smoking Cessation & Opioid Dependence Treatment Integration NCT02854800	West Virginia University	Phase 2 / Phase 3
Completed	Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers NCT02750748	National Institute on Drug Abuse (NIDA)	Phase 1
Unknown	Buccal Versus Injectable Naloxone: a Phase I Healthy Volunteer Study NCT02733822	King's College London	Phase 1
Completed	Conflict Between Maternal Autonomy and Child Health in Substance-use NCT02797990	London School of Hygiene and Tropical Medicine	—
Completed	Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Use Disorder NCT02669901	University of New Mexico	N/A
Completed	Interferon-free Antiviral Treatment of Chronic Hepatitis C Virus Infection Among Opioid-substituted Patients NCT02969668	Universitätsklinikum Hamburg-Eppendorf	—
Completed	Validation of PRISM-5-Op, Measure Of Addiction To Prescription Opioid Medication NCT02660619	Member Companies of the Opioid PMR Consortium	—
Completed	Prevalence and Predictors of Prolonged Post-surgical Opioid Use: a Prospective Observational Cohort Study NCT02571400	University of Notre Dame Australia	—
Completed	Study of the Treatment of Experimental Pain in Buprenorphine Maintained Persons With Chronic Musculoskeletal P NCT02372591	Johns Hopkins University	Phase 1
Completed	An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery NCT03604861	Indivior Inc.	—
Completed	Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder NCT02510014	Indivior Inc.	Phase 3
Terminated	Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disor NCT03143543	Virginia Commonwealth University	Phase 1
Completed	An Observational Study to Develop Algorithms for Identifying Opioid Abuse and Addiction Based on Admin Claims NCT02667262	Member Companies of the Opioid PMR Consortium	—
Completed	Study to Validate Coded Medical Terms Used to Identify Opioid-Related Overdose in Databases Used for PMR Study NCT02667197	Member Companies of the Opioid PMR Consortium	—
Completed	A Quantitative Study to Assess the Construct Validity of the Prescription Opioid Misuse and Abuse Questionnair NCT02678507	Member Companies of the Opioid PMR Consortium	—
Completed	Cross-Sectional Study to Define and Validate "Doctor/Pharmacy Shopping" as Outcomes Suggestive of Abuse and/or NCT02668549	Member Companies of the Opioid PMR Consortium	—
Completed	Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Bupreno NCT02357901	Indivior Inc.	Phase 3
Completed	A Qualitative Study to Assess the Content Validity of the Prescription Opioid Misuse and Abuse Questionnaire NCT02660606	Member Companies of the Opioid PMR Consortium	—
Completed	Interim Buprenorphine: Leveraging Medication + Technology to Bridge Delays in Treatment Access NCT02360007	University of Vermont Medical Center	Phase 1 / Phase 2
Completed	Pupil Response in Patients on Opioids. NCT02247024	Oslo University Hospital	—
Completed	A Survey to Eval the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or NCT02667158	Member Companies of the Opioid PMR Consortium	—
Completed	Study to Eval Relation Btw Doctor/Pharmacy Shopping & Outcomes of Misuse, Diversion, Abuse, Addiction by Med R NCT02667210	Member Companies of the Opioid PMR Consortium	—
Completed	Safety and Health Intervention Project NCT02152397	University of Michigan	N/A
Completed	Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers NCT02572089	National Institute on Drug Abuse (NIDA)	Phase 1
Completed	Phone Interview to Prevent Recurring Opioid Overdoses NCT02282306	University of Cincinnati	N/A
Completed	Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Naloxone Recipients NCT02093559	San Francisco Department of Public Health	N/A
Completed	Influence of Dexmedetomidine and Lidocaine on Opioid Consumption in Laparoscopic Intestine Resection NCT02616523	University Medical Centre Ljubljana	Phase 4
Completed	Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry NCT01999946	NYU Langone Health	Phase 4
Completed	Transforming Opioid Prescribing in Primary Care NCT01909076	Boston Medical Center	N/A
Completed	Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Admini NCT01880086	Weill Medical College of Cornell University	Phase 2
Completed	Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Depende NCT01848054	Orexo AB	Phase 3
Completed	A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocai NCT01846481	Indivior Inc.	Phase 2
Completed	Safety & Prevention Outcomes Study NCT01894087	University of Michigan	N/A
Completed	Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid U NCT01759446	Acura Pharmaceuticals Inc.	Phase 2
Completed	Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT NCT01471145	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Phase 4
Completed	Neurocognitive Effects of Opiate Agonist Treatment NCT01733693	Albert Einstein College of Medicine	Phase 4
Completed	Variation of COMT Val158Met Polymorphism Between COM-ON Patients and METHADOSE Patients NCT01570699	Assistance Publique - Hôpitaux de Paris	—
Terminated	Comparative Evaluation of PUSPENs and C&Cs NCT02698098	University of Malaya	—
Terminated	Pioglitazone to Treat Opioid Withdrawal Symptoms NCT01517165	National Institute on Drug Abuse (NIDA)	Phase 1
Completed	Studies of Opioid Seeking Behavior: Yohimbine and Hydrocortisone Effects NCT01536925	Wayne State University	—
Completed	A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery NCT01374763	Kati Järvelä	Phase 4
Completed	Drug-Drug Interaction Study Between Telaprevir and Buprenorphine NCT01275599	Vertex Pharmaceuticals Incorporated	Phase 1
Completed	Medications Development for Drug Abuse Disorders NCT01188421	Johns Hopkins University	Phase 1 / Phase 2
Completed	Medication-Assisted Treatment Implementation in Community Correctional Environments (MATICCE) NCT01344122	Rhode Island Hospital	N/A
Completed	Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release NCT01595867	Pfizer	Phase 1
Completed	A Clinical Study To Characterize The Pharmacokinetics And The Effects Of Food On Oxycodone In Healthy Voluntee NCT01530542	Pfizer	Phase 1
Completed	Study of Computer-Based Treatment for Drug Dependence NCT01315184	Yale University	Phase 2
Unknown	Trial of Methadone Maintenance Versus Methadone Detox in Jail NCT01874964	The Miriam Hospital	N/A
Completed	Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users NCT01108679	Albert Einstein College of Medicine	—
Completed	Methylnaltrexone for Opioid-induced Constipation in Cancer Patients NCT01004393	University of Vermont	Phase 2
Completed	Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2 NCT00000299	University of California, Los Angeles	Phase 2
Completed	Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal NCT00723177	New York State Psychiatric Institute	Phase 2
Completed	Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients NCT00780702	National Institute on Drug Abuse (NIDA)	Phase 1
Terminated	Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among In NCT00270257	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3
Completed	Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P0 NCT00725608	Indivior Inc.	—
Completed	Treatment Study: Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine (ARC) NCT00698737	Wayne State University	—
Completed	Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Stu NCT00723749	Indivior Inc.	—
Completed	Effects of Stress and Other Factors on Opiate Drug Choice. NCT00684840	Wayne State University	—
Completed	Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone NCT00637000	Indivior Inc.	Phase 2
Completed	Safety and Tolerability of Buprenorphine/Naloxone Film Strips NCT00640835	Indivior Inc.	Phase 2
Unknown	Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers NCT00726960	Karolinska University Hospital	Phase 1
Completed	Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial NCT00684554	New York State Psychiatric Institute	Phase 2 / Phase 3
Completed	Abuse Liability of Suboxone Versus Subutex NCT00710385	New York State Psychiatric Institute	Phase 3
Completed	Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Dru NCT00734461	Pain Therapeutics	Phase 2
Completed	Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland NCT00473993	Seidenberg, Arztpraxis A., M.D.	—
Completed	Effects of Environmental Factors on Opiate Drug Choice in Opioid Dependent Individuals. NCT00608504	Wayne State University	—
Suspended	The Effects of Pharmacotherapy on Brain Mechanisms Underlying Cocaine Dependence. NCT00396734	Hadassah Medical Organization	N/A
Completed	Buprenorphine's Dose Response Curve NCT00460239	Johns Hopkins University	Phase 2
Completed	Sustained Release d-Amphetamine & Buprenorphine on Drug Seeking Behavior in Opioid & Cocaine Dependent Individ NCT00429767	Wayne State University	—
Completed	Dextromethorphan, Gabapentin, and Oxycodone to Treat Opioid-Induced Hyperalgesia NCT00218374	National Institute on Drug Abuse (NIDA)	N/A
Completed	Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1 NCT00142935	The Miriam Hospital	N/A
Completed	Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions NCT00992095	Roxane Laboratories	N/A
Completed	Buprenorphine HIV Care Integration Project NCT00348868	University of Miami	N/A
Completed	Addiction Treatment in Russia: Oral vs. Naltrexone Implant NCT00218426	University of Pennsylvania	Phase 2 / Phase 3
Completed	Study of Buprenorphine Maintenance Treatment for Opioid Dependence in Primary Care NCT00471042	New York State Psychiatric Institute	—
Completed	Prescription Opioid Addiction Treatment Study (POATS) NCT00316277	Mclean Hospital	Phase 3
Completed	Assessment of Tramadol as a Treatment for Opioid Addiction NCT00301210	Johns Hopkins University	Phase 1 / Phase 2
Completed	Interactive Voice Response (IVR) for Methadone Patients NCT00237406	Butler Hospital	—
Completed	Employment-based Reinforcement of Naltrexone Ingestion and Abstinence NCT00149669	Johns Hopkins University	N/A
Completed	Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients NCT00295308	National Institute on Drug Abuse (NIDA)	Phase 1
Completed	Effects of Post-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals NCT00218361	Wayne State University	—
Unknown	Buprenorphine and Integrated HIV Care Evaluation NCT00124358	The New York Academy of Medicine	Phase 4
Completed	RCT Comparing Methadone and Buprenorphine in Pregnant Women NCT00271219	Johns Hopkins University	Phase 3
Completed	Project BEST: Buprenorphine Entry Into Substance Abuse Treatment NCT02583243	Yale University	—
Completed	Addition of Naltrexone to Methadone Taper NCT00135759	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1 NCT00142909	Yale University	Phase 2
Completed	Tramadol to Reduce Opioid Withdrawal Symptoms NCT00142896	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Prescription Opioid Effects in Abusers Versus Non-Abusers NCT00158184	New York State Psychiatric Institute	Phase 2
Terminated	Abuse Potential of Buprenorphine/Naloxone NCT00149539	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Buprenorphine as a Treatment for Individuals Dependent on Analgesic Opioids NCT00218101	National Institute on Drug Abuse (NIDA)	Phase 2
Terminated	Opioid Agonist and Antagonist Effects on Opioid Dependence NCT00142727	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals NCT00218309	National Institute on Drug Abuse (NIDA)	—
Completed	Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1 NCT00078130	University of Pennsylvania	Phase 3
Completed	Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1 NCT00078117	University of California, Los Angeles	Phase 3
Completed	The Therapeutic Workplace Initiation Study NCT00249470	Johns Hopkins University	N/A
Completed	Comparison of Buprenorphine and Methadone - 3 NCT00000334	National Institute on Drug Abuse (NIDA)	Phase 2
Withdrawn	Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6 NCT00000331	University of Colorado, Denver	Phase 2
Terminated	Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone NCT00000243	National Institute on Drug Abuse (NIDA)	N/A
Completed	Fetal Neurobehavioral Development in Methadone Maintained Pregnancies NCT00067184	Johns Hopkins University	—
Completed	Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens NCT00218127	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Lofexidine for Opiate Withdrawal - 1 NCT00032942	National Institute on Drug Abuse (NIDA)	Phase 3
Completed	Fluoxetine to Reduce Cocaine Use in Cocaine and Opioid Addicts NCT00142779	National Institute on Drug Abuse (NIDA)	N/A
Completed	Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone NCT00218608	University of Arkansas	Phase 2
Terminated	Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers NCT00134875	National Institute of Allergy and Infectious Diseases (NIAID)	N/A
Completed	Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence NCT00134888	National Institute on Drug Abuse (NIDA)	N/A
Completed	Methadone Levels in Breast Milk of Women Taking Methadone for Opiate Addiction - 2 NCT00218010	National Institute on Drug Abuse (NIDA)	—
Completed	Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1 NCT00023283	Yale University	Phase 2
Withdrawn	Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5 NCT00000330	University of Colorado, Denver	Phase 2
Completed	HIV Counseling Intervention for Methadone-Maintained Patients - 2 NCT00061100	New York State Psychiatric Institute	Phase 1
Withdrawn	Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4 NCT00000329	University of Colorado, Denver	Phase 2
Completed	Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocain NCT00000240	University of Vermont	Phase 2
Completed	Effect Of Case Management Following Discharge From Methadone Treatment NCT00018226	US Department of Veterans Affairs	Phase 2
Completed	Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1 NCT00061087	New York State Psychiatric Institute	Phase 2 / Phase 3
Completed	Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13 NCT00000261	University of Chicago	Phase 2
Completed	Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1 NCT00000320	National Institute on Drug Abuse (NIDA)	Phase 1 / Phase 2
Completed	Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16 NCT00000264	University of Chicago	N/A
Completed	Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20 NCT00000238	National Institute on Drug Abuse (NIDA)	Phase 2
Withdrawn	Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3 NCT00000328	University of Colorado, Denver	Phase 2
Completed	Subjective Effects of Nitrous Oxide in Dental Patients - 17 NCT00000265	University of Chicago	—
Completed	Effects of Behavioral Contingencies on Effects of Nitrous Oxide - 12 NCT00000260	University of Chicago	N/A
Withdrawn	Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2 NCT00000327	University of Colorado, Denver	Phase 2
Completed	Buprenorphine Detoxification - BBDVI - 19 NCT00000237	National Institute on Drug Abuse (NIDA)	Phase 2
Withdrawn	Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1 NCT00000326	University of Colorado, Denver	Phase 2
Completed	Effects of Combined Alcohol and Nitrous Oxide Intake - 15 NCT00000263	University of Chicago	N/A
Completed	Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users NCT00158236	National Institute on Drug Abuse (NIDA)	N/A
Completed	Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1 NCT00000352	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Buprenorphine and Naloxone Combination Study - 10 NCT00015288	National Institute on Drug Abuse (NIDA)	Phase 1
Completed	Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14 NCT00000262	University of Chicago	N/A
Completed	Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1 NCT00015028	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2 NCT00015041	National Institute on Drug Abuse (NIDA)	Phase 1
Completed	Trial of Buprenorphine/Naloxone for Opiate Dependence - 2 NCT00000353	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Evaluation of Liquid vs. Tablet Buprenorphine - 6 NCT00000341	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11 NCT00000259	University of Chicago	N/A
Completed	Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence NCT00134914	National Institute on Drug Abuse (NIDA)	N/A
Completed	Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3 NCT00000354	National Institute on Drug Abuse (NIDA)	Phase 1
Completed	Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2 NCT00000319	Yale University	Phase 2
Completed	Role of Instructions in Nitrous Oxide Effects and Choice - 10 NCT00000258	University of Chicago	N/A
Completed	Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10 NCT00000345	National Institute on Drug Abuse (NIDA)	Phase 1
Completed	Buprenorphine Detox With Two Types of Treatment. BBD II - 11 NCT00000229	University of Vermont	Phase 2
Completed	Activity Monitoring Assessment of Opiate Withdrawal - 4 NCT00000335	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Effects of Alcohol History on Effects of Nitrous Oxide - 9 NCT00000257	University of Chicago	N/A
Completed	A Laboratory Model for Heroin Abuse Medications - 8 NCT00000273	New York State Psychiatric Institute	Phase 2
Completed	Buprenorphine Combination Tablet Feasibility - 1 NCT00000298	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8 NCT00000256	University of Chicago	N/A
Completed	Differential Acute Tolerance Development to Effects of Nitrous Oxide - 7 NCT00000255	University of Chicago	Phase 2
Completed	Feasibility Study of Take-Home LAAM Medication - 3 NCT00000300	University of California, Los Angeles	Phase 4
Completed	Combining Behavioral Treatment With Agonist Maintenance - 1 NCT00000311	Yale University	Phase 3
Completed	Isoflurane at Subanesthetic Concentrations - 6 NCT00000254	University of Chicago	Phase 2
Completed	Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12 NCT00000230	University of Vermont	Phase 2
Completed	Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1 NCT00000318	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Effects of Nitrous Oxide: A Dose-Response Analysis - 5 NCT00000253	University of Chicago	N/A
Completed	Effects of Buprenorphine and Naloxone in Opiate Addicts - 4 NCT00000355	National Institute on Drug Abuse (NIDA)	Phase 1
Completed	Alternate-Day Buprenorphine Administration. Phase VII - 8 NCT00000226	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Novel Medications for Opiate Detoxification - 4 NCT00000279	Yale University	Phase 2
Completed	Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3 NCT00000306	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Effects of Dynorphin 1-13 on Heroin Addiction - 1 NCT00000244	University of Minnesota	Phase 2
Completed	Buprenorphine Detox With Two Types of Treatment. BBD I - 10 NCT00000228	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Alternate-Day Buprenorphine Administration. Phase VIII - 9 NCT00000227	University of Vermont	Phase 2
Completed	Lack of Acute Tolerance Development to Effects of Nitrous Oxide - 4 NCT00000252	University of Chicago	Phase 2
Completed	Effects of Subanesthetic Concentrations of Isoflurane/Nitrous Oxide - 3 NCT00000251	University of Chicago	Phase 2
Completed	Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2 NCT00000250	University of Chicago	Phase 2
Completed	Effects of Subanesthetic Concentrations of Nitrous Oxide - 1 NCT00000249	University of Chicago	Phase 2
Completed	Alternate-Day Buprenorphine Administration. Phase IV - 5 NCT00000223	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Alternate Day Buprenorphine Administration, Phase X - 15 NCT00000233	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Alternate-Day Buprenorphine. Phase V - 6 NCT00000224	National Institute on Drug Abuse (NIDA)	Phase 1
Withdrawn	Neurobiology of Opioid Dependence: 3 - 3 NCT00000194	Yale University	Phase 2
Withdrawn	Neurobiology of Opioid Dependence: 5 - 5 NCT00000196	Yale University	Phase 2
Withdrawn	Neurobiology of Opioid Dependence: 2 - 2 NCT00000193	Yale University	Phase 2
Withdrawn	Neurobiology of Opioid Dependence: 1 - 1 NCT00000192	Yale University	Phase 2
Withdrawn	Neurobiology of Opioid Dependence: 4 - 4 NCT00000195	Yale University	Phase 2
Completed	Alternate-Day Buprenorphine Administration. Phase VI - 7 NCT00000225	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Buprenorphine Dosing Interval - 5 NCT00000209	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Alternate-Day Buprenorphine Administration. Phase II - 4 NCT00000222	National Institute on Drug Abuse (NIDA)	Phase 1
Completed	Buprenorphine Maintenance for Opiate Dependence - 6 NCT00000357	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Multicenter Clinical Trial of Buprenorphine - 3 NCT00000207	University of California, Los Angeles	Phase 3
Completed	Alternate-Day Buprenorphine Administration. Phase I - 3 NCT00000221	National Institute on Drug Abuse (NIDA)	Phase 1
Completed	Alternate Day Buprenorphine Administration, Phase IX - 14 NCT00000232	University of Vermont	Phase 2
Completed	Methadone/Buprenorphine Cross-Over Study - 4 NCT00000208	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13 NCT00000231	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Buprenorphine Dose Alteration Study - 1 NCT00000219	University of Vermont	Phase 1
Completed	Gradual Vs. Rapid Buprenorphine Detoxification - 2 NCT00000220	National Institute on Drug Abuse (NIDA)	Phase 1
Completed	Evaluation of L-alpha-acetylmethadol (LAAM) in Methadone Patients - 5 NCT00000356	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Clinical Rescue Protocol - 2 NCT00000206	University of California, Los Angeles	Phase 2
Completed	Buprenorphine Maintenance Protocol - 1 NCT00000205	University of California, Los Angeles	Phase 3
Completed	Buprenorphine Maintenance for Opioid Addicts - 1 NCT00000202	Yale University	Phase 2
Completed	Buprenorphine Maintenance for Opioid Addicts - 3 NCT00000204	Yale University	Phase 2
Completed	Buprenorphine Maintenance for Opioid Addicts - 2 NCT00000203	Yale University	Phase 2
Completed	Alternate Day Buprenorphine Administration, Phase XII - 17 NCT00000235	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Alternate Day Buprenorphine Administration, Phase XI - 16 NCT00000234	University of Vermont	Phase 2
Unknown	Surveillance Monitoring of Opioid Abuse in Poison and Drug Treatment Centers NCT02871232	ER/LA Opioid REMS Program Companies (RPC)	—
Unknown	Evaluation of Changes in Prescribing Behavior of ER/LA Opioid Prescribers NCT02920762	ER/LA Opioid REMS Program Companies (RPC)	—
Completed	Buprenorphine Pharmacology Related to Addiction Treatment - 21 NCT00000239	National Institute on Drug Abuse (NIDA)	Phase 2
Completed	Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1 NCT00000216	Yale University	Phase 3
Unknown	ER/LA Opioid Surveillance for Emergency Department Visits and Hospitalizations for Overdose and Poisoning NCT02866266	ER/LA Opioid REMS Program Companies (RPC)	—
Completed	Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7 NCT00000358	National Institute on Drug Abuse (NIDA)	Phase 1
Unknown	Monitoring Patterns of Prescribing to Identify Changes in Access to ER/LA Opioid Analgesics NCT02920775	ER/LA Opioid REMS Program Companies (RPC)	—
Completed	Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9 NCT00000344	National Institute on Drug Abuse (NIDA)	Phase 2
Unknown	ER/LA Opioid Analgesics - Surveillance Monitoring of State Medical Examiner Databases NCT02897414	ER/LA Opioid REMS Program Companies (RPC)	—
Unknown	Evaluation of Drug Utilization Patterns for Extended Release/Long Acting Opioids and Comparator Products NCT02925806	ER/LA Opioid REMS Program Companies (RPC)	—
Completed	Buprenorphine Pharmacology Related to Addiction Treatment - 18 NCT00000236	National Institute on Drug Abuse (NIDA)	Phase 2